EA032913B1 - Препараты производных пиримидиндиона - Google Patents

Препараты производных пиримидиндиона

Info

Publication number
EA032913B1
EA032913B1 EA201791354A EA201791354A EA032913B1 EA 032913 B1 EA032913 B1 EA 032913B1 EA 201791354 A EA201791354 A EA 201791354A EA 201791354 A EA201791354 A EA 201791354A EA 032913 B1 EA032913 B1 EA 032913B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrimidinedione derivative
derivative compounds
formulations
methods
pharmaceutical compositions
Prior art date
Application number
EA201791354A
Other languages
English (en)
Russian (ru)
Other versions
EA201791354A2 (ru
EA201791354A3 (ru
Inventor
Янься Ли
Пин Гао
И Ши
Хао Хоу
Майкл Мэкэплоу
Келли Э. Мидоуз
Джефф Дж. Чжан
И Гао
Original Assignee
Эббви Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эббви Инк. filed Critical Эббви Инк.
Publication of EA201791354A2 publication Critical patent/EA201791354A2/ru
Publication of EA201791354A3 publication Critical patent/EA201791354A3/ru
Publication of EA032913B1 publication Critical patent/EA032913B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201791354A 2012-10-18 2013-10-18 Препараты производных пиримидиндиона EA032913B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261715766P 2012-10-18 2012-10-18

Publications (3)

Publication Number Publication Date
EA201791354A2 EA201791354A2 (ru) 2017-11-30
EA201791354A3 EA201791354A3 (ru) 2018-03-30
EA032913B1 true EA032913B1 (ru) 2019-08-30

Family

ID=49554481

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791354A EA032913B1 (ru) 2012-10-18 2013-10-18 Препараты производных пиримидиндиона
EA201590752A EA028481B1 (ru) 2012-10-18 2013-10-18 Препараты производных пиримидиндиона

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590752A EA028481B1 (ru) 2012-10-18 2013-10-18 Препараты производных пиримидиндиона

Country Status (11)

Country Link
US (2) US9629841B2 (enExample)
EP (1) EP2908808A1 (enExample)
JP (2) JP6266635B2 (enExample)
CN (2) CN104853752B (enExample)
AU (1) AU2013330993B2 (enExample)
BR (1) BR112015008927A2 (enExample)
CA (1) CA2888883A1 (enExample)
EA (2) EA032913B1 (enExample)
MX (1) MX2015004973A (enExample)
SG (1) SG11201503051QA (enExample)
WO (1) WO2014063101A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
US20230119355A1 (en) * 2020-03-05 2023-04-20 Aurigene Discovery Technologies Limited Pharmaceutical compositions of a kinase inhibitor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200200954A1 (ru) * 2000-04-19 2003-04-24 Смитклайн Бичем Пи-Эл-Си Композиция
EA200300450A1 (ru) * 2000-10-11 2003-08-28 Сефалон, Инк. Фармацевтические растворы соединений модафинила
US20070082952A1 (en) * 2005-10-06 2007-04-12 Benjamin Eric J Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof
EA013741B1 (ru) * 2004-12-15 2010-06-30 Элан Фарма Интернэшнл Лтд. Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4442257A1 (de) * 1994-11-28 1996-05-30 Beate Dr Podschun Sparsomycin
DK1083885T3 (da) 1998-06-11 2007-02-26 Pharmacia & Upjohn Co Llc Delavirdintabletformulering
OA12124A (en) 1999-12-23 2006-05-05 Pfizer Prod Inc Pharmmaceutical compositions providing enhanced drug concentrations.
EP2725015A1 (en) * 2007-09-17 2014-04-30 AbbVie Bahamas Ltd. Uracil or thymine derivative for treating hepatitis c
US20100166861A1 (en) * 2008-12-29 2010-07-01 Kelly Noel Lynch Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone
AU2011223895A1 (en) * 2010-03-01 2012-09-13 Concert Pharmaceuticals Inc. Fluorouracil derivatives
SG2014011670A (en) * 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200200954A1 (ru) * 2000-04-19 2003-04-24 Смитклайн Бичем Пи-Эл-Си Композиция
EA200300450A1 (ru) * 2000-10-11 2003-08-28 Сефалон, Инк. Фармацевтические растворы соединений модафинила
EA013741B1 (ru) * 2004-12-15 2010-06-30 Элан Фарма Интернэшнл Лтд. Дисперсии наночастиц такролимуса с повышенными растворимостью в воде и биодоступностью, способы их приготовления и применения
US20070082952A1 (en) * 2005-10-06 2007-04-12 Benjamin Eric J Pharmaceutical compositions, methods of preparation thereof, and methods of treatment
WO2009039134A1 (en) * 2007-09-17 2009-03-26 Abbott Laboratories Anti-infective pyrimidines and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Raymond C. Rowe et al. Handbook of Pharmaceutical Excipients. 2009, № 6, p. 917, с. 129-132, 185-187, 206, 207 *
Sree Giri Prasad. B et al. Formulation and Evaluation of Oro Dispersible Tablets of Stavudine by Direct Compression Technique. Scholar Research Library. Der Pharmacia Lettre, 2012, 4(5):p.1505-1514, с. 1505, последний абзац, с. 1506, абзац 1, с. 1509, абзац 3, табл. 1-3 *
КАРЛИНА М.В. и др. Фармакокинетика куркуминоидов в составе препарата "артрофлекс". Химико-фармацевтический журнал, 2007, т. 41, № 10, с. 3-5, с. 1, кол. 1, последний абзац, кол. 2, абзац 1 *

Also Published As

Publication number Publication date
CN104853752B (zh) 2018-10-23
AU2013330993A1 (en) 2015-05-07
CN104853752A (zh) 2015-08-19
SG11201503051QA (en) 2015-05-28
AU2013330993B2 (en) 2018-03-01
US20140113921A1 (en) 2014-04-24
US9629841B2 (en) 2017-04-25
EA201791354A2 (ru) 2017-11-30
JP6266635B2 (ja) 2018-01-24
JP2015534985A (ja) 2015-12-07
EA201590752A1 (ru) 2016-02-29
WO2014063101A1 (en) 2014-04-24
EA201791354A3 (ru) 2018-03-30
MX2015004973A (es) 2015-07-17
JP2018065858A (ja) 2018-04-26
US10201542B2 (en) 2019-02-12
EA028481B1 (ru) 2017-11-30
BR112015008927A2 (pt) 2017-07-04
CA2888883A1 (en) 2014-04-24
EP2908808A1 (en) 2015-08-26
US20170181973A1 (en) 2017-06-29
CN109260207A (zh) 2019-01-25

Similar Documents

Publication Publication Date Title
JOP20180102A1 (ar) مركب صيدلاني
IN2014MN02598A (enExample)
MX2015008628A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IL244206A0 (en) A pharmaceutical preparation containing a pyrimidine compound as an active ingredient
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2013001677A (es) Formulaciones estables de linaclotida.
IN2014MN00988A (enExample)
GEP201706774B (en) Heterocyclyl compounds
GB201106743D0 (en) Novel compounds
UA109010C2 (en) Morpholino pyrividines and their use in therapy
UA117122C2 (uk) Хінолонові похідні
PH12015501096A1 (en) Composition for immediate and extended release
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
IN2015DN01119A (enExample)
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
TN2012000488A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2014010433A (es) Nueva forma cristalina de sulfato de sitagliptina.
UA117154C2 (uk) Антагоністи s1p3
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX366829B (es) Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas.
EA032913B1 (ru) Препараты производных пиримидиндиона
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
WO2014166836A8 (en) Growth hormone compound formulation
IN2015DN00085A (enExample)
MX355719B (es) Composicion farmaceutica en forma de una suspension oral que comprende una fraccion flavonoica y goma de xantano.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU